Unknown

Dataset Information

0

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.


ABSTRACT:

Background

QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting ?2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose bronchodilator combination of tiotropium plus formoterol (TIO+FOR) in improving health-related quality of life (HRQoL) of patients with COPD.

Methods

This multicentre, blinded, triple-dummy, parallel-group, non-inferiority study randomised patients aged ?40?years with moderate-to-severe COPD (post-bronchodilator forced expiratory volume in 1?s (FEV1) ?30% to <80% predicted) to QVA149 110/50?µg o.d. or TIO 18?µg o.d.+ FOR 12?µg twice daily (1:1) for 26?weeks. The primary endpoint was to demonstrate non-inferiority in HRQoL assessed using St George's Respiratory Questionnaire-COPD (SGRQ-C). The prespecified non-inferiority margin was 4 units. Secondary endpoints included Transition Dyspnoea Index (TDI) score, pre-dose FEV1, forced vital capacity (FVC) and safety.

Results

Of the 934 patients randomised (QVA149=476 and TIO+FOR=458), 87.9% completed the study. At week 26, non-inferiority was met for SGRQ-C (QVA149 vs TIO+FOR; difference: -0.69 units; 95% CI -2.31 to 0.92; p=0.399). A significantly higher percentage of patients achieved a clinically relevant ?1 point improvement in TDI total score with QVA149 (49.6%) versus TIO+FOR (42.4%; p=0.033). QVA149 significantly increased pre-dose FEV1 (+68?mL, 95% CI 37?mL to 100?mL; p<0.001) and FVC (+74?mL, 95% CI 24?mL to 125?mL; p=0.004) compared with TIO+FOR at week 26. The incidence of adverse events was comparable between both treatments (QVA149=43.7% and TIO+FOR=42.6%).

Conclusions

QVA149 is non-inferior to TIO+FOR in improving HRQoL, with clinically meaningful and significant improvements in breathlessness and lung function in patients with COPD.

Trial registration number

NCT01120717.

SUBMITTER: Buhl R 

PROVIDER: S-EPMC4392202 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.

Buhl Roland R   Gessner Christian C   Schuermann Wolfgang W   Foerster Karin K   Sieder Christian C   Hiltl Simone S   Korn Stephanie S  

Thorax 20150212 4


<h4>Background</h4>QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose bronchodilator combination of tiotropium plus formoterol (TIO+FOR) in improving health-related quality of life (HRQoL) of patients with COPD.<h4>Methods</h4>This multicentre, blinded, triple-dummy, parallel-gr  ...[more]

Similar Datasets

| S-EPMC3282675 | biostudies-literature
| S-EPMC5073218 | biostudies-literature
| S-EPMC4094569 | biostudies-literature
| S-EPMC4152473 | biostudies-literature
| S-EPMC4029330 | biostudies-literature
| S-EPMC5318624 | biostudies-literature
| S-EPMC6217915 | biostudies-literature
| S-EPMC3233513 | biostudies-literature
| S-EPMC3594701 | biostudies-literature
| S-EPMC4645961 | biostudies-literature